-
1.发明公开公开(公告)号：US20240122984A1
公开(公告)日：2024-04-18
申请号：US18403553
申请日：2024-01-03
发明人： Matthias Stephan
IPC分类号： A61K35/17 , A01K67/0271 , A61K9/00 , A61K9/14 , A61K39/44 , A61K45/06 , C07K16/28 , C12N5/09
CPC分类号： A61K35/17 , A01K67/0271 , A61K9/0024 , A61K9/146 , A61K39/44 , A61K45/06 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C12N5/0694 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , C12N2510/00 , C12N2533/54 , C12N2533/74
摘要： The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
-
公开(公告)号：US11445742B2
公开(公告)日：2022-09-20
申请号：US17110585
申请日：2020-12-03
摘要： A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.
-
公开(公告)号：US20210347816A1
公开(公告)日：2021-11-11
申请号：US17239195
申请日：2021-04-23
申请人： BAC IP B.V.
摘要： The invention relates to a method of immunoaffinity purification which comprises the use of a binding agent which binds to an epitope that is present at least twice on the target molecule. In another embodiment the method uses at least two different binding agents, each binding to different epitopes on the target molecule.
-
公开(公告)号：US20210346504A1
公开(公告)日：2021-11-11
申请号：US17380388
申请日：2021-07-20
IPC分类号： A61K47/42 , A61K35/36 , A61K9/127 , A61K47/58 , A61K47/62 , A61K47/68 , A61K39/00 , A61K47/69 , A61K39/44
摘要： The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy.
-
公开(公告)号：US20210268106A1
公开(公告)日：2021-09-02
申请号：US17326009
申请日：2021-05-20
发明人： Michael Har-Noy
IPC分类号： A61K39/39 , A61K38/19 , A61K38/21 , A61K39/085 , A61K38/17 , A61K35/17 , A61K38/20 , C12N5/0783 , A61K39/385 , A61K39/44
摘要： The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.
-
公开(公告)号：US11071783B2
公开(公告)日：2021-07-27
申请号：US15559314
申请日：2016-03-21
发明人： Barton F. Haynes , Hua-Xin Liao , M. Anthony Moody , LaTonya Williams , Kevin J. Wiehe , Gilad Adi Ofek
摘要： The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.
-
公开(公告)号：US11059879B2
公开(公告)日：2021-07-13
申请号：US15771128
申请日：2016-10-27
IPC分类号： C07K14/705 , A61K39/44 , A61K39/00 , A61K39/395 , A61P35/02 , A61P35/00 , C07K14/725 , C07K16/28 , A61K38/00
摘要： Chimeric antigen receptor (CAR) polypeptides are provided comprising an antigen binding domain; a hinge domain; a transmembrane domain and an intracellular signaling domain, wherein the CAR polypeptide binds to a target antigen and wherein the antigen binding domain comprises HCDR sequences from a first antibody that binds to the target antigen and LCDR sequences from a second antibody that binds to the target antigen. In certain aspects, the target antigen is CD123.
-
公开(公告)号：US11052155B2
公开(公告)日：2021-07-06
申请号：US15461560
申请日：2017-03-17
申请人： SYNTARGA BV
发明人： Patrick Henry Beusker , Rudy Gerardus Elisabeth Coumans , Ronald Christiaan Elgersma , Wiro Michael Petrus Bernardus Menge , Johannes Albertus Frederikus Joosten , Henri Johannes Spijker , Franciscus Marinus Hendrikus De Groot
IPC分类号： A61K39/44 , A61K47/64 , A61K31/437 , C07D471/04 , A61K47/65 , A61K47/60 , A61K47/54 , A61K38/38 , A61K47/68
摘要： This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
-
公开(公告)号：US11045541B2
公开(公告)日：2021-06-29
申请号：US14962728
申请日：2015-12-08
发明人： Michael Har-Noy
IPC分类号： A61K39/00 , A61K39/39 , A61K38/19 , A61K38/21 , A61K39/085 , A61K38/17 , A61K35/17 , A61K38/20 , C12N5/0783 , A61K39/385 , A61K39/44
摘要： The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.
-
公开(公告)号：US11001820B2
公开(公告)日：2021-05-11
申请号：US15407589
申请日：2017-01-17
申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS , The Kitasato Institute , MONTEFIORE MEDICAL CENTER , NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
发明人： Tulasi Ponnapakkam , Sagaya Theresa Leena Philominathan , Joshua Sakon , Ranjitha Katikaneni , Takaki Koide , Osamu Matsushita , Robert C. Gensure , Nozomu Nishi
IPC分类号： C12N9/52 , A61K38/29 , A61K38/19 , A61K38/30 , A61K39/395 , A61K8/49 , A61K8/65 , A61Q7/00 , A61K47/64 , A61K8/64 , A61K8/66 , A61K38/17 , A61K38/18 , A61K39/44 , A61Q7/02 , A61K38/27 , C07K14/475 , C07K14/485 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/51 , C07K14/535 , C07K14/61 , C07K14/71 , C07K16/18 , A61K39/00 , A61K38/00
摘要： Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
-
-
-
-
-
-
-
-
-
搜索结果
874 条记录 (耗时 0.035 秒)
